Clinical Efficacy of Shugan Huazhuo Zhenyang Prescription in Treatment of Chronic Prostatitis Combined with Erectile Dysfunction
10.13422/j.cnki.syfjx.20242422
- VernacularTitle:疏肝化浊振阳方治疗慢性前列腺炎合并勃起功能障碍的临床观察
- Author:
Zuzhen YAN
1
;
Zongjiang ZHAO
2
Author Information
1. Beijing Chaoyang Jinzhan Second Community Health Service Center， Beijing 100018， China
2. Beijing University of Chinese Medicine， Beijing 100029， China
- Publication Type:Journal Article
- Keywords:
chronic prostatitis;
erectile dysfunction;
Shugan Huazhuo Zhenyang prescription;
randomized control;
clinical research
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2025;31(8):135-142
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the clinical efficacy of Shugan Huazhuo Zhenyang prescription in treating patients with chronic prostatitis （CP） complicated by erectile dysfunction （ED）. MethodsThis study is a randomized controlled trial， which enrolled 90 CP patients with ED from Professor ZHAO Zongjiang's outpatient clinic. The patients were randomly divided into a treatment group and a control group in a 1∶1 ratio， with 45 patients in each group. The treatment group received the Shugan Huazhuo Zhenyang prescription， while the control group received Sildenafil citrate tablets. Both treatments lasted for 4 weeks. Baseline data， including age， body mass index （BMI）， and disease duration， were collected before and after treatment. Clinical efficacy， chronic prostatitis symptom score （CPSI）， international erectile function questionnaire （IIEF-5）， erection hardness score （EHS）， traditional Chinese medicine （TCM） syndrome score， and routine changes in prostate fluid were compared and analyzed between the two groups to evaluate the effectiveness and safety of the treatments for CP combined with ED. ResultsThere were no statistically significant differences in general information between the two groups. After treatment， the treatment group showed a significant decrease in the CPSI score and an increase in the IIEF-5 score （P<0.05）. The differences in EHS ratings and TCM syndrome scores were statistically significant （P<0.05）. Compared to the control group， there were significant differences in CPSI scores and TCM syndrome scores （P<0.05）. Although the clinical efficacy and IIEF-5 score in the treatment group improved after treatment， the differences were not statistically significant. After treatment， the white blood cells， red blood cells， and pus cells in the prostate fluid of the treatment group decreased compared to the control group， while lecithin bodies increased. The differences between the two groups were statistically significant （P<0.01）. No significant abnormalities were found in the safety evaluations. ConclusionShugan Huazhuo Zhenyang prescription can improve symptoms such as pain， discomfort， abnormal urination， moist scrotum， weak erection， premature ejaculation， and erectile dysfunction. It is an effective treatment for CP complicated by ED.
